Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Breckenridge Pharmaceutical has said that it has settled paragraph IV litigation with Novartis concerning Trileptal and that the FDA has approved Breckenridge's abbreviated new drug application for oxcarbazepine 150mg, 300mg and 600mg tablets in the US.
Subscribe to our email newsletter
Breckenridge has completed a shared 180-day exclusivity period and will immediately launch oxcarbazepine tablets 150mg, 300mg, and 600mg. Oxcarbazepine tablets are AB rated to Trileptal which is being used in treating seizures.